Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents. The North American pediatric cooperative groups have performed a series of clinical treatment trials in this disease over the past several decades, and biology studies of tumor tissue have been an important study component. A meeting was held in Bethesda, Maryland on November 29-30, 2001, sponsored by the NIH Office of Rare Diseases, the Children's Oncology Group, and the National Cancer Institute-Cancer Therapy Evaluation Program with the general objectives: (a) to review the current state of knowledge regarding OS biology; (b) to identify, prioritize, and support the development of biology studies of potential clinical relevance in OS; and (c) to discuss the available tissue resources and the appropriate methods for analysis of OS samples for the conduct of biology studies. This report summarizes the information presented and discussed by the meeting participants.
Gorlick
Richard
R
Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Anderson
Peter
P
Andrulis
Irene
I
Arndt
Carola
C
Beardsley
G Peter
GP
Bernstein
Mark
M
Bridge
Julia
J
Cheung
Nai-Kong
NK
Dome
Jeffrey S
JS
Ebb
David
D
Gardner
Thomas
T
Gebhardt
Mark
M
Grier
Holcombe
H
Hansen
Marc
M
Healey
John
J
Helman
Lee
L
Hock
Janet
J
Houghton
Janet
J
Houghton
Peter
P
Huvos
Andrew
A
Khanna
Chand
C
Kieran
Mark
M
Kleinerman
Eugenie
E
Ladanyi
Marc
M
Lau
Ching
C
Malkin
David
D
Marina
Neyssa
N
Meltzer
Paul
P
Meyers
Paul
P
Schofield
Deborah
D
Schwartz
Cindy
C
Smith
Malcolm A
MA
Toretsky
Jeffrey
J
Tsokos
Maria
M
Wexler
Leonard
L
Wigginton
Jon
J
Withrow
Stephen
S
Schoenfeldt
Mason
M
Anderson
Barry
B
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000235:genetics / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D002648:Child; D006801:Humans; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D012516:Osteosarcoma / Q000235:genetics / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy
D020533:Angiogenesis Inhibitors